Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation

Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation

Abstract Background This study was designed to investigate the difference between brain metastases (BM) and non-brain metastases (non-BM) treated by osimertinib in advanced patients with an acquired EGFR T790M mutation after obtaining first-generation EGFR-TKI resistance. Methods A total number of 1...

Full description

Bibliographic Details
Main Authors: Changhui Li, Wei Nie, Jingdong Guo, Anning Xiong, Hua Zhong, Tianqing Chu, Runbo Zhong, Jianlin Xu, Jun Lu, Xiaoxuan Zheng, Bo Zhang, Yinchen Shen, Feng Pan, Baohui Han, Xueyan Zhang
Format: Article
Language:English
Published: BMC 2021-05-01
Series:Respiratory Research
Subjects:
Osimertinib
Brain metastases
EGFR T790M mutation
Radiotherapy
Online Access:https://doi.org/10.1186/s12931-021-01741-9

Internet

https://doi.org/10.1186/s12931-021-01741-9

Similar Items